SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001387131-22-001711
Filing Date
2022-02-11
Accepted
2022-02-11 17:12:14
Documents
1
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITYI, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITYI, LLCATLAS VENTURE ASSOCIATES X, L.P.ATLAS VENTURE ASSOCIATES X,LLCATLAS VENTURE ASSOCIATES XI, L.P.ATLAS VENTURE ASSOCIATES XI,LLCATLAS VENTURE FUND XI, L.P.ATLAS VENTURE OPP

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ikena-sc13d_021122.htm SC 13D 192756
  Complete submission text file 0001387131-22-001711.txt   194650
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund X, L.P. (Filed by) CIK: 0001628098 (see all company filings)

IRS No.: 472435989 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 50 NORTHERN AVE. BOSTON MA 02210
Business Address 50 NORTHERN AVE. BOSTON MA 02210 857-343-8292
Ikena Oncology, Inc. (Subject) CIK: 0001835579 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92449 | Film No.: 22622637
SIC: 2836 Biological Products, (No Diagnostic Substances)